The company has received a notice of approval for a Swedish patent covering the antimicrobial mechanism of action in its treatment patch, M045A, developed for the treatment of oral ulcers caused by aphthae (Recurrent Aphthous Stomatitis).

The patent approval strengthens the company’s intellectual property portfolio and represents an important milestone ahead of the international PCT application planned for spring 2026, it states. The antimicrobial mechanism is a central component of the M045A technology and is considered to be of great importance in the pursuit of an effective treatment for recurrent oral ulcers caused by aphthae.

“The patent approval gives us a solid foundation to build upon. The technology has great potential, not only for aphthae, but also in other areas where the combination of hygroscopy and antimicrobial action can provide significant clinical benefits,” says Project Manager Jean Lycke.